Richard R. Blough

Northwestern University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Lary J. Kilton

Barrington Public Library

Thomas E. Lad

Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics

Al B. Benson

Northwestern University

Suzanne French

Northwestern University

Harvey M. Golomb

University of Chicago

Merrill S. Kies

The University of Texas MD Anderson Cancer Center

Richard H. Knop

NorthShore University HealthSystem

Carole M. Johnson

Illinois Arts Council Agency

Michael Russell Mullane

Cook County Health and Hospitals System

James L. Wade

Decatur Memorial Hospital

Cooperative Institutions

University of Chicago

Northwestern University

University of Illinois Chicago

University of Chicago Medical Center

Cancer Research Center

NorthShore University HealthSystem

University of Illinois Urbana-Champaign

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Rush University Medical Center

Northwestern Memorial Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Phase II trial of menogaril in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial.

PubMed (1987)

Gershon Y. Locker Lary J. Kilton Thomas Hoeltgen Richard H. Knop Al B. Benson

Toxicite du menogaril (leucopenie et erytheme au point d'injection). Pas d'efficacite therapeutique

Source

Cite

Citations (1)

Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas

Investigational New Drugs (1992)

Lary J. Kilton Al B. Benson Alice Greenberg Patricia Lynn Johnson Charles L. Shapiro

Leukopenia

Bolus (digestion)

10.1007/bf00877246

Cite

Citations (11)

Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease.

Journal of Clinical Oncology (1988)

Roula Farah J E Ultmann Melvin L. Griem Harvey M. Golomb U. Kalokhe

Between 1968 and 1983, 135 patients with pathologic stage (PS) I and II Hodgkin's disease were treated with extended mantle radiation technique (EMRT) at Michael Reese Hospital and the University of Chicago Center for Radiation Therapy. EMRT combines both standard mantle and para-aorta fields (M-PA) in one port. Actuarial disease-free survival at 5 and 10 years was 82.5%. Actuarial overall survival was 96% and 83% at 5 and 10 years, respectively. Acute complications were evaluated in 112 patients available for analysis. Severe nausea and vomiting occurred in 13%, weight loss of greater than 10% of body weight in 19%, and acute hematologic toxicity in 4% of patients. Bone marrow suppression was transient and did not interfere with subsequent delivery of salvage treatment with either chemotherapy or radiation therapy in 22 patients who relapsed. The cost of EMRT is 40% lower than the cost of treatment with M-PA. The median treatment time was 38 days, 33% less than the 56 days for M-PA field assuming no interruptions. These results suggest that the EMT is a safe and effective treatment tolerated by most patients. The advantages of this method are eliminating the possibility of technical error of matching between mantle and para-aortic field, decreasing overall treatment time, and reducing the cost.

10.1200/jco.1988.6.6.1047

Cite

Citations (48)

Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck

Investigational New Drugs (1995)

Fred Rosen Everett E. Vokes Thomas E. Lad Merrill S. Kies James L. Wade

10.1007/bf00873808

Cite

Citations (3)

Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study.

PubMed (1986)

J. E. Harris Tanvi Gupta N. Vogelzang K Badrinath P. Bonomi

Twenty patients with soft tissue sarcoma were treated with iv human fibroblast interferon (beta-interferon). Each cycle of treatment involved 5 X 10(6) units over 10 minutes, then 5 X 10(6) units iv over 3 hours daily X 10 with cycles repeated every 20 days X 3. Maintenance therapy was given twice weekly if disease was stable or responsive after three therapy periods. One patient had a partial response to treatment and six patients experienced stable disease for variable periods of time. Toxicity (fever, fatigue, leukopenia, hepatic enzyme elevations) was moderate and tolerable; therapy (except in one case of profound granulocytopenia) was neither interrupted nor discontinued because of toxicity. We conclude that beta-interferon in the dose and schedule used has limited value for soft tissue sarcoma.

Leukopenia

Interferon alfa

Source

Cite

Citations (7)

Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck

Investigational New Drugs (1994)

Merrill S. Kies David L. Grinblatt Melissa Runge‐Morris Richard R. Blough Arletrice Watkins

Melphalan

Squamous carcinoma

10.1007/bf00873235

Cite

Citations (1)

Profound Sensorineural Deafness: A Histopathologic Study

Annals of Otology Rhinology & Laryngology (1987)

Raúl Hinojosa Richard R. Blough Ernest E. Mhoon

For this study 22 temporal bones from patients with profound sensorineural deafness of various causes were selected. Graphic reconstruction of each cochlea and acoustic ganglion was performed, together with a quantitative evaluation of three types of sensorineural elements: hair cells, peripheral auditory fibers, and ganglion cells. The numbers of acoustic ganglion cells were compared with those in 16 normal temporal bones. The temporal bones were divided into five groups, based on the relative degree of degeneration found in each of the three types of elements studied. Severe to complete hair cell loss was noted in all five groups; degeneration of peripheral nerve fibers ranged from moderate to complete in all but one group; and ganglion cell counts varied widely within all groups. In a qualitative comparison no relationship was found between the clinical data and the histopathologic correlates. The results of the study suggest that neither the clinical data nor the histopathologic findings provide any criteria for selecting patients for cochlear implants.

Spiral ganglion

Sensorineural deafness

Degeneration (medical)

10.1177/00034894870960s120

Cite

Citations (24)

Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A phase ii study by the illinois cancer council

Cancer (1985)

Max Haid Janardan D. Khandekar Miriam L. Christ Carole M. Johnson Stephen J. Miller

Aziridinylbenzoquinone (AZQ) was studied in a Phase II protocol for persons with glioma of the central nervous system (CNS) recurrent or progressive after surgery and radiotherapy. Patients received AZQ, 30 mg/m2 intravenously every 3 weeks if previously untreated or 27.5 mg/m2 if previously exposed to cytotoxic drugs. Partial response was defined as a reduction of at least 50% reduction in the product of the two longest perpendicular diameters of the indicator lesion persisting for a minimum of 28 days. Twenty-eight patients are evaluable for response at this time. Objective response (OR) occurred in four (14.3%): two complete and two partial. Stabilization of disease (SD) was seen in 7 (25.0%). Median survival, in weeks, was greater than 46.0 for responders, 41.7 for SD, and 19.3 for those with progressive disease. The survival experiences are significantly different (P = 0.030 [Breslow]). The OR rate was 21.1% in 19 without prior chemotherapy and 0% in 9 previously treated patients. There were two AZQ-related deaths in patients with prior exposure to nitrosoureas (1 CNS hemorrhage; 1 aspiration pneumonia). One patient had an anaphylactic reaction. Three patients whose tumor initially increased in size subsequently had marked tumor shrinkage. AZQ is an active agent that must be used with added caution in patients who have received nitrosoureas. Initial tumor enlargement may precede response. Although response appears to prolong survival, the correlation between stabilization of disease and survival is not well-defined.

10.1002/1097-0142(19850915)56:6<1311::aid-cncr2820560615>3.0.co;2-v

Cite

Citations (21)

Spiral ganglion cell survival in labyrinthitis ossificans: computerized image analysis.

PubMed (1995)

Raúl Hinojosa Miriam Redleaf J D Green Richard R. Blough

Obstruction of the cochlear scale by ossification and fibrosis, which can now be imaged by computed tomography, has been proposed as a predictor of ganglion cell survival. Subjects for this histopathologic temporal bone study were 12 profoundly deaf patients with labyrinthitis ossificans. Controls without ossification were 16 normal-hearing patients and 16 profoundly deaf patients. All temporal bones were graphically reconstructed. Computerized image analysis obtained the percentage of scalar obstruction in 12 temporal bones with labyrinthitis ossificans. Statistical analyses could demonstrate no relationship between spiral ganglion cell survival and obstruction. There was much interindividual variability in ganglion cell count among the 44 temporal bones. Ganglion cell survival was significantly less in the two deafness groups than in the normal group, but did not differ significantly between the two deafness groups. Therefore, cochlear labryinthitis ossificans is not a preditor of ganglion cell survival and should not be a contraindication to cochlear implantation.

Spiral ganglion

Labyrinthitis

Source

Cite

Citations (14)

Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.

PubMed (1987)

Locker Gy Thomas Hoeltgen Larry Kilton S Krauß M. McNamara

Source

Cite

Citations (4)